Literature DB >> 16001414

No going home for hospitalized Huntington's disease patients.

Richard M Dubinsky1.   

Abstract

Little is known as to what happens to people with Huntington's disease (HD) at the end of life. Exploratory analysis was performed for all admissions of people with HD in the Nationwide Inpatient Sample database, a 20% stratified sample of all US hospitalizations, from 1996 to 2002. Using the principal diagnosis and procedure, admission cohorts were determined. The common HD-associated reasons for admission were pneumonia (including aspiration, 22%), psychiatric (21.5%), debilitation (hypovolemia, nutritional deficiencies, and decubitus ulcers, 15.5%), trauma (5.7%), and nonpulmonary infections (urinary tract infections and sepsis, 11.%). Twenty-two percent were admitted for medical problems unrelated to HD. Emergency departments were the most frequent source of admission (60%), most had Medicare or Medicaid as the expected payer (80.6%), 54.4% of all admissions were discharged to long-term care facilities (LTCFs), and 3.7% died. The highest mortality was seen in the pneumonia (7.68%) and sepsis (7.39%) cohorts. Of the elective admissions, between 49.71% and 60.31% were discharged to LTCFs, representing new LTCF admissions. Based on this exploratory analysis, hospitalized HD patients are admitted late in the course of their illness, are severely disabled, and are commonly discharged to LTCFs. With 60.31% of the discharges representing new LTCF admissions, this finding shows that there is no going home from the hospital for people with HD. Copyright (c) 2005 Movement Disorder Society.

Entities:  

Mesh:

Year:  2005        PMID: 16001414     DOI: 10.1002/mds.20589

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  Hospital Admissions of Huntington's Disease Patients in a Huntington's Disease Centre Between 2011 and 2016: A Retrospective Analysis.

Authors:  Marina Peball; Beatrice Heim; Philipp Ellmerer; Florian Frank; Nadia Busin; Matyas Galffy; Atbin Djamshidian; Klaus Seppi
Journal:  Mov Disord Clin Pract       Date:  2022-05-05

Review 2.  Neuroprotection for Huntington's disease: ready, set, slow.

Authors:  Steven M Hersch; H Diana Rosas
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

3.  An Australian Neuro-Palliative perspective on Huntington's disease: a case report.

Authors:  Rajvi Shah; Sarah Cm Lee; Rupert B Strasser; Christopher Grossman
Journal:  BMC Palliat Care       Date:  2021-04-01       Impact factor: 3.234

4.  Hospitalizations of Children with Huntington's Disease in the United States.

Authors:  Adys Mendizabal; Anh-Thu Ngo Vu; Dylan Thibault; Pedro Gonzalez-Alegre; Allison Willis
Journal:  Mov Disord Clin Pract       Date:  2017-09-11

5.  Inpatient gastrostomy in Huntington's disease: Nationwide analysis of utilization and outcomes compared to amyotrophic lateral sclerosis.

Authors:  Ali G Hamedani; Meredith Pauly; Dylan P Thibault; Pedro Gonzalez-Alegre; Allison W Willis
Journal:  Clin Park Relat Disord       Date:  2020-01-24

6.  Disparities in Palliative Care Utilization Among Hospitalized People With Huntington Disease: A National Cross-Sectional Study.

Authors:  Leonard L Sokol; Danny Bega; Chen Yeh; Benzi M Kluger; Hillary D Lum
Journal:  Am J Hosp Palliat Care       Date:  2021-07-22       Impact factor: 2.090

7.  The Spectrum of Psychiatric Pathology in a Patient with Genetically Verified Huntington's Disease.

Authors:  Samir Alkabie; Daljinder Singh; Amy Hernandez; Rhaisa Dumenigo
Journal:  Case Rep Psychiatry       Date:  2015-09-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.